Clinical trials: Gardasil Vaccine
Papillomavirus Infections, Uterine Cervical Neoplasms
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam.
- Conditions
- Papillomavirus Infections, Uterine Cervical Neoplasms, Vulvar Neoplasms, Vaginal Neoplasms
- Trial name
- NCT03546842
- Testing
- 9vHPV vaccine
- Where
- Vietnam
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
HPV, Cervical Cancer
Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)
This dose-ranging study is to evaluate an investigational vaccine with the following objectives: (1) To demonstrate that the vaccine is well-tolerated in women (2) To evaluate immune responses in women who are between 16 and 23…
- Conditions
- HPV, Cervical Cancer, Premalignancy Anogenital Warts
- Trial name
- NCT00260039
- Testing
- Comparator: Gardasil, Comparator: octavalent HPV Vaccine - dose formulation 1, Comparator: octavalent HPV Vaccine - dose formulation 2
- Volunteers
- 680 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus
Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.
Two human papillomavirus vaccines are now commercially available. No clinical data exist regarding: The immunogenicity and safety of Gardasil and Twinrix when co-administered.
- Trial name
- NCT01456715
- Testing
- Gardasil vaccine, Immunogenicity, Booster dose., Cervarix Vaccine, Immunogenicity, Booster Dose.
- Where
- Canada
- Volunteers
- 418 people, healthy volunteers welcome
- Sponsor
- Laval University
Cervical Cancer, Cervical Intraepithelial Neoplasia
V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)
This study evaluated the long-term safety of quadrivalent Human Papillomavirus (HPV) types 6, 11, 16, 18 vaccine and its effectiveness in the prevention of cervical intraepithelial neoplasia (CIN), adenocarcinoma in situ, and…
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia, Adenocarcinoma in Situ
- Trial name
- NCT01544478
- Testing
- V501
- Volunteers
- 1,030 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papilloma Virus Infection Type 16
Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination
The current study is an open-label, non-randomized, longitudinal exploratory trial using the licensed Gardasil 9 (9vHPV) vaccine in an off-label context to investigate biological and immunological outcomes in human papillomavirus…
- Trial name
- URVIVE (NCT07407569)
- Testing
- Gardasil 9 (2 dose regimen)
- Where
- 3 sites in Belgium
- Volunteers
- 50 people
- Sponsor
- Universiteit Antwerpen
Human Papillomavirus Vaccines
Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9
This study will assess the immunogenicity of one dose of Gardasil and one dose of Gardasil-9
- Trial name
- NCT03431246
- Testing
- Gardasil and Gardasil-9
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Laval University
Systemic Lupus Erythematosus
Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients
Cervical neoplasia is increased in women with SLE most likely due to cervical infection with human papilloma virus (HPV). 70% of cervical cancer is caused by HPV types 16 and 18.
- Trial name
- GARDASIL (NCT01741012)
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Wayne State University
Human Papilloma Virus
Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City
In the genital tract human papilloma virus (HPV), especially types 6 and 11 cause genital warts, the commonest viral sexually transmitted disease.
- Trial name
- NCT02382900
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine
- Where
- Mexico
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universidad Nacional Autonoma de Mexico
Cervical Cancer, Vulvar Cancer
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
This study will assess the safety and immunogenicity of GARDASIL®9 (V503) in 16- to 45-year-old women. The primary hypothesis of the study states that anti-HPV 16, 18, 31, 33, 45, 52, and 58 geometric mean titers (GMTs) at 4…
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT03158220
- Testing
- V503
- Where
- 24 sites in Austria, Belgium and 4 more
- Volunteers
- 1,212 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papilloma Viral Infection
A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)
Primary objective To demonstrate that administration of V503 induces non-inferior Geometric Mean Titres (GMTs) for serum anti-HPV 6, 11, 16, and 18, compared to GARDASIL in 16- to 26-year-old men
- Trial name
- NCT02114385
- Testing
- V503, GARDASIL
- Where
- 7 sites in Belgium, Germany and 1 more
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus Virus
Observational Follow up of Prior HPV Vaccinees
HPV vaccines have been included in the national immunisation schedule since 2008, firstly as the Cervarix vaccine which protects against two HPV types and in 2012 as the Gardasil vaccine which offers protection against a further…
- Trial name
- HPVfollowup (NCT02811068)
- Testing
- venepuncture
- Where
- 2 sites in United Kingdom
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Public Health England
Gardasil Vaccine, Stem Cell Transplant
Gardasil Vaccination in Post Stem Cell Transplant Patients
Background: Gardasil , a recently approved vaccine for the sexually transmitted human papillomavirus (HPV), provides immunity to four types of HPV that are associated with genital warts and cervical, vaginal, and vulvar precancer…
- Conditions
- Gardasil Vaccine, Stem Cell Transplant, Immunogenicity
- Trial name
- NCT01092195
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Human Papilloma Virus, HPV
Acceptance of Human Papillomavirus Vaccination in Postpartum Women
Worldwide cervical cancer remains a major cause mortality among women. It is estimated that each year over 490,000 women are diagnosed with cervical cancer and more than 270,000 die from the disease.
- Conditions
- Human Papilloma Virus, HPV, Post Partum
- Trial name
- HPV Acceptance (NCT00730704)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Columbia University
Cervical Cancer
Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making
Preventing cervical cancer is a public health concern. Since 2006 a quadrivalent vaccine for young women nine to twenty six years of age has been available to protect against the human papillomavirus (HPV) and to prevent some…
- Trial name
- NCT00807898
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Cervical Cancer, Genital Warts
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
The primary purpose of the study is to determine if GARDASIL (V501) with four components is able to prevent cervical cancer, cervical dysplasia, including Cervical Intraepithelial Neoplasia (CIN)(Any Grade) and Adenocarcinoma In…
- Trial name
- NCT00092521
- Testing
- V501, Human Papillomavirus (HPV) 16 Monovalent
- Volunteers
- 5,759 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus
KAP/WTP and HPV Prevalence Studies in a Developing World Setting (Bamako, Mali)
The Global Alliance to Immunize Against AIDS Vaccine Foundation (GAIA Vaccine Foundation or GAIA VF) proposes to carry out a Knowledge, Attitudes, and Practices (KAP) study in conjunction with a Willingness To Participate (WTP)…
- Trial name
- HPV (NCT01314404)
- Where
- 2 sites in Mali
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Global Alliance to Immunize Against AIDS Vaccine Foundation
Cervical Cancer, Condylomata Acuminata
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
This study is designed to compare plateau antibody levels of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females…
- Trial name
- NCT06197802
- Testing
- Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9
- Where
- China
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Cervical Cancer
Phase 3 Trial of a Bivalent Human Papilloma Virus (HPV) Vaccine (Cecolin®) in Young Girls
This randomized controlled trial will evaluate a bivalent HPV vaccine, Cecolin®, in alternate 2-dose regimens, compared to an established HPV vaccine.
- Trial name
- NCT04508309
- Testing
- Cecolin®, Gardasil®
- Where
- 2 sites in Bangladesh, Ghana
- Volunteers
- 1,025 people, healthy volunteers welcome
- Sponsor
- PATH
Uterine Cervical Cancer
Community Awareness, Resources and Education (CARE II): Project 3
Researchers at The Ohio State University and the University of Michigan are working together to understand cancer of the cervix.
- Trial name
- NCT01299714
- Where
- 4 sites in United States
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Human Papillomavirus (HPV) Infection
GARDASIL Reexamination Study (V501-059)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of Gardasil through collecting…
- Trial name
- NCT01062074
- Volunteers
- 3,605 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC